110884-53-2 Usage
General Description
5-Methoxy-1H-pyrazol-3-amine hydrochloride is a chemical compound that belongs to the class of pyrazole derivatives. It is commonly used in the field of pharmaceutical research and development as a building block for the synthesis of various bioactive compounds. 5-Methoxy-1H-pyrazol-3-aMine hydrochloride has potential applications in the development of drugs targeting various diseases and conditions. It is typically used as a reagent in organic synthesis and medicinal chemistry processes, and its hydrochloride salt form provides better solubility in water, making it easier to handle and use in laboratory settings. Overall, 5-Methoxy-1H-pyrazol-3-amine hydrochloride is an important intermediate in the production of pharmaceutical and biologically active compounds, and it plays a crucial role in the advancement of drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 110884-53-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,8,8 and 4 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 110884-53:
(8*1)+(7*1)+(6*0)+(5*8)+(4*8)+(3*4)+(2*5)+(1*3)=112
112 % 10 = 2
So 110884-53-2 is a valid CAS Registry Number.
110884-53-2Relevant articles and documents
Discovery of 5-chloro- N 2-[(1 S)-1-(5-fluoropyrimidin-2-yl) ethyl]- N 4-(5-methyl-1 H -pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the jak/stat pathway
Ioannidis, Stephanos,Lamb, Michelle L.,Wang, Tao,Almeida, Lynsie,Block, Michael H.,Davies, Audrey M.,Peng, Bo,Su, Mei,Zhang, Hai-Jun,Hoffmann, Ethan,Rivard, Caroline,Green, Isabelle,Howard, Tina,Pollard, Hannah,Read, Jon,Alimzhanov, Marat,Bebernitz, Geraldine,Bell, Kirsten,Ye, Minwei,Huszar, Dennis,Zinda, Michael
, p. 262 - 276 (2011)
The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematological malignancies characterized by clonal expansion of one or more myeloid lineages. The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs. Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor. 9e inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent physical properties and preclinical pharmacokinetics, and is currently being evaluated in Phase I clinical trials.
